Compare · ATOS vs NVO
ATOS vs NVO
Side-by-side comparison of Atossa Therapeutics Inc. (ATOS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATOS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 5044.8x ATOS ($37.9M).
- Over the past year, ATOS is down 80.8% and NVO is down 44.7% - NVO leads by 36.1 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for ATOS).
- NVO has more recent analyst coverage (25 ratings vs 0 for ATOS).
- Company
- Atossa Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $2.55-41.91%
- $43.52+1.72%
- Market cap
- $37.9M
- $191.15B
- 1M return
- -51.01%
- -7.32%
- 1Y return
- -80.78%
- -44.68%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2012
- News (4w)
- 4
- 8
- Recent ratings
- 0
- 25
Atossa Therapeutics Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ATOS
- Atossa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
- Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
- Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
- Director Steinhart Richard I was granted 10,000 shares (SEC Form 4)
- Director Chen Shu-Chih was granted 10,000 shares (SEC Form 4)
- Director Remmel H. Lawrence was granted 10,000 shares, increasing direct ownership by 1,464% to 10,683 units (SEC Form 4)
- Director Finn Jonathan was granted 10,000 shares, increasing direct ownership by 600% to 11,666 units (SEC Form 4)
- Director Galli Stephen J was granted 10,000 shares, increasing direct ownership by 166,667% to 10,006 units (SEC Form 4)
- Director Cigler Tessa was granted 10,000 shares (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care